- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02218151
Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2
Patient-Centered Medical Home Care for Hematopoietic Stem Cell Transplantation: A Randomized Phase 2 Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The patient-centered medical home (PCMH) is an exciting strategy that has the potential to revolutionize hematopoietic stem cell transplantation (HCT). Traditionally, home care has been used for palliative care in end-stage cancer patients and in geriatrics. More recently the PCMH has gained increasing adoption for both primary care and care of medically complex patients. The core of the PCMH lies in the interaction between the healthcare team, the patient's family and support, and above all, the patient. These interactions can be enhanced through health information technologies such as the electronic health record (EHR) and videoconferencing via iPads. In addition, collection of patient reported outcomes (PRO) will allow feedback and adjustments.
This integration is especially important when considering the multiple complicated needs of the HCT patient: navigating a Byzantine healthcare system that often requires input and coordination from multiple specialists including transplanters, hematologists, infectious disease physicians, gastroenterologists, psychiatrists, nutritionists, pharmacists, social workers, financial coordinators, etc.; managing medication regimens to prevent infections, GVHD, and other complications (not to mention avoiding drug and food interactions); adjusting to multiple side effects including fatigue, weakness, anorexia, nausea, vomiting, diarrhea, rashes, pain, anxiety, stress, organ failure, etc.; the sheer amount of time required for healthcare visits, lab draws, waiting for results, infusions, transfusions, etc.; physical and psychosocial struggles of living with a life-threatening disease; and the burdens of a treatment that often seems as debilitating as the disease. The PCMH provides patient-centered, comprehensive, accessible, and coordinated care and a systems-based approach to quality and safety: these attributes are essential to the successful care of the complicated HCT patient. this approach has the potential to lower overall costs while preserving or increasing the quality of care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nelson J Chao, MD, MBA
- Phone Number: 919-668-1011
- Email: nelson.chao@duke.edu
Study Contact Backup
- Name: Anthony D Sung, MD
- Phone Number: 919-668-1002
- Email: anthony.sung@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Adult Bone Marrow Transplant Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Scheduled to undergo a hematopoietic stem cell transplant for any cancer or non-cancer illness
- Age 18-80 years of age
- Karnofsky Performance Scale (KPS)> 80
- A home that is deemed, upon inspection, in suitable condition to serve as a medical home, within a 90-minute driving distance of Duke
Exclusion Criteria:
- Lack of a caregiver
- Pregnant women
- Patients with a documented active infection prior to starting their preparative regimen. This includes grade 3 or higher viral, bacterial, or fungal infection.
- Use of homeopathic medications or probiotics that may impact gut microbiota
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient-Centered Medical Home (PCMH)
Day-to-Day Care: Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria. Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects. |
Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home.
Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care.
They will draw labs and bring them back to the hospital for processing.
When results are available, a second home visit is made to deliver necessary interventions.
Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians.
Daily follow up at home will continue until discharge as per above criteria.
|
Active Comparator: Standard Care
These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self. Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects. |
Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient.
Advanced practice providers (APPs) will perform histories and physical exams.
Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Graft Versus Host Disease (aGVHD)
Time Frame: 6 months
|
The primary endpoint is the incidence (number of events) of grade II-IV acute GVHD at 6 months.
GVHD will be evaluated daily by advanced practice providers (APPs) according to standard criteria.
The investigators will compare GVHD incidence rates between treatment arms using survival type regression modeling that takes competing risks into account.
They will examine cause-specific Cox proportional hazards models as well as the proportional subdistribution hazard regression model developed by Fine and Gray.
While the primary treatment comparison will be unadjusted, adjustment for covariates to explore the impact of various risk factors will also be performed.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Infection
Time Frame: 1 year
|
Rates of bacterial, fungal, and viral infections as well as overall infections at one year.
|
1 year
|
Disease Free Survival (DFS)
Time Frame: 1 year
|
Disease free survival at one year.
|
1 year
|
Overall Survival
Time Frame: 1 year
|
Overall survival at one year.
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Gut Microbiota
Time Frame: 6 months
|
Shannon diversity index will be compared using unpaired two-sided Student's t tests with a more stringent cut-off of 0.0125 given multiple comparisons, by the Bonferroni correction for 4 time periods of independent comparisons.
Comparisons of bacterial populations will be made by using the Adonis non-parametric method from within the Qiime package using UnifFrac distance matrices from the populations being compared.
P values will be calculated with α= 0.05.
Metastatistics will be used for further statistical analyses of population structure, membership, and diversity with metadata such as time from transplant and dietary measurements such as caloric intake.
Changes in specific bacterial families of interest will be compared using a two-sided Student's t test, with normality confirmed by D'Agostino and Pearson omnibus test with p≤0.05.
All other comparisons will be done using two-sided Mann-Whitney tests.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nelson J C, MD, MBA, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00051024
- R01CA203950-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Disorders
-
AHEPA University HospitalCompletedCoagulation Disorder | Extracorporeal Circulation; Complications | Extracorporeal Circulation of Blood; ThrombocytopeniaGreece
-
BioMarin PharmaceuticalActive, not recruitingHemophilia A | Gene Therapy | Blood Disorder | Clotting DisordersTaiwan, Korea, Republic of, United Kingdom, South Africa
-
University of UtahRecruitingCoagulation Disorder, BloodUnited States
-
Seoul National University HospitalSeoul National University Bundang HospitalCompleted
-
Seoul National University Bundang HospitalCompleted
-
Leiden University Medical CenterCompletedBlood Coagulation Disorder
-
University of RochesterTerminatedBlood Coagulation DisorderUnited States
-
ShireCompletedThrombocythemia, EssentialSpain, United Kingdom, Greece, Denmark, Italy, France, Finland, Norway, Sweden, Germany, Cyprus, Ireland, Netherlands, Portugal
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruitingBlood Coagulation Disorder
-
Seoul National University Bundang HospitalRecruiting
Clinical Trials on Patient-Centered Medical Home (PCMH)
-
University of Illinois at ChicagoPatient-Centered Outcomes Research InstituteCompleted
-
Geriatric Education and Research InstituteNational Healthcare Group, Singapore; Tsao FoundationCompletedQuality of Life | Health Services | Delivery of Health Care | Costs and Cost AnalysisSingapore
-
Oslo University HospitalVirginia Commonwealth University; Sunnaas Rehabilitation HospitalCompletedTraumatic Brain InjuryNorway
-
University of Kansas Medical CenterPatient-Centered Outcomes Research InstituteCompleted
-
Ohio State UniversityCompletedChronic Disease | Communication Research | Advance Care PlanningUnited States
-
Philipps University Marburg Medical CenterUnknownHealthy ParticipantsGermany
-
Universitair Ziekenhuis BrusselHasselt University; Ziekenhuis Oost-Limburg; Vrije Universiteit Brussel; Kom Op...RecruitingBreast Cancer | Breast Neoplasms | SurgeryBelgium
-
Dartmouth-Hitchcock Medical CenterNational Institute of Mental Health (NIMH)CompletedDepression | Schizophrenia | Schizoaffective Disorder | Bipolar DisorderUnited States
-
Public Health Foundation Enterprises, Inc.ViiV Healthcare; San Francisco Department of Public Health; Lyon-Martin Community...Recruiting
-
CNGE ConseilRecruitingColorectal Cancer ScreeningFrance